Sequella Inc.
This article was originally published in Start Up
Executive Summary
Sequella Inc. believes that the technology to meet antibiotic-resistant mycobacterium tuberculosis already exists. The company will acquire intellectual property rights to product opportunities in TB.
You may also be interested in...
Drug Resistance Start-Ups: Is Resistance Futile?
Overcoming drug resistance is a key goal of development--but will anyone fund it?
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.